# Medical Question & Answer

**Sample ID**: 514a4ced-b9d9-4132-94e3-b7f259772b98
**Dataset Index**: 4276

---

## Question

Does Vyvanse pass into breast milk?

---

## Answer

> Let's see… What do we have here? The user is asking whether Vyvanse (lisdexamfetamine) passes into breast milk. Let's break this down step-by-step. First, I need to think about the active moiety and pharmacology that govern milk transfer. Then, I should review the FDA label lactation data for Vyvanse and corroborate across the amphetamine class. Next, I will quantify infant exposure using the relative infant dose framework, but I need to double-check the math and the assumptions. After that, I should examine reported infant outcomes and long-term uncertainties, consider effects on milk production, and finally synthesize the regulatory recommendation with practical counseling points and potential alternatives.

> Let me first confirm the pharmacology, because if I get the active entity wrong, all subsequent inferences about milk transfer will be off. Vyvanse is a pro-drug rapidly converted in vivo to dextroamphetamine, so the relevant exposure in human milk pertains to amphetamine rather than lisdexamfetamine itself, which frames both the transfer kinetics and the infant exposure considerations.

> Next, I should review the core lactation data on the Vyvanse label. Wait, let me verify the exact figures: the FDA labeling states that based on limited case reports, amphetamine (d- or d, l-) appears in human milk, with relative infant doses of 2% to 13.8% of the maternal weight-adjusted dosage, and a milk-to-plasma ratio between 1.9 and 7.5; there are no reported adverse effects on breastfed infants in these case reports, but long-term neurodevelopmental effects remain unknown.

> I need to check whether this is product-specific or a class-consistent signal. Cross-checking other amphetamine-containing products, Adzenys XR-ODT, Mydayis, and Adderall XR carry essentially the same lactation language, including similar relative infant dose ranges, milk-to-plasma ratios, and the same bottom-line: advise that breastfeeding is not recommended during treatment due to potential for serious adverse reactions in nursing infants, which supports the interpretation as a class effect rather than an isolated Vyvanse phenomenon [^111zoF5V] [^113R1yyv] [^113pXK2f].

> Now I will quantify infant exposure to make this concrete, but I should proceed carefully. My first back-of-the-envelope calculation goes like this: if a mother takes 30–70 mg/day and weighs ~70 kg, the maternal dose per kg is ~0.43–1 mg/kg; applying a 2–13% RID would suggest an infant receives ~0.0086–0.13 mg/kg/day, or for a 5 kg infant, roughly 0.043–0.65 mg/day; earlier I mistakenly wrote 0.6–9 mg/day, which is clearly too high for these assumptions, so let me correct that now and emphasize the proper RID formula use [^113R1yyv]. But wait, I should also note a methodological caveat: the RID cited in labeling is derived for amphetamine exposure, whereas my quick calculation used lisdexamfetamine tablet strengths; since the provided materials do not furnish a validated lisdexamfetamine-to-dextroamphetamine mg conversion table, this exact mg/day translation is imprecise, and the safer inference is to keep the exposure framed in relative terms (2–13.8% RID) rather than absolute milligrams without additional product-specific conversion data [^113R1yyv].

> Hold on, let's not jump to conclusions from "no adverse reports". I need to examine infant outcomes carefully. The Vyvanse label notes no case reports of adverse effects in breastfed infants, but explicitly states that long-term neurodevelopmental effects are unknown, which is a crucial uncertainty that tempers reassurance; broader lactation safety reviews further note that serious acute adverse drug reactions via breast milk appear uncommon overall, though infants under 2 months are more susceptible and deserve heightened caution and monitoring if exposure occurs [^113R1yyv] [^1116vYDb] [^1129YUSB].

> I should confirm potential effects on milk production because that also alters risk–benefit considerations for the dyad. The FDA labeling cautions that large dosages of dextroamphetamine may interfere with milk production, plausibly via dopaminergic suppression of prolactin; mechanistically, this aligns with the observation that antidopaminergic agents such as domperidone raise prolactin and increase milk supply, highlighting the biological plausibility that amphetamines may reduce it, particularly when lactation is not yet well established [^113R1yyv] [^114orzZh].

> Next, I will review the FDA's explicit recommendation, because that ultimately guides clinical advice. The Vyvanse label advises that breastfeeding is not recommended during treatment due to the potential for serious adverse reactions in nursing infants, including serious cardiovascular reactions, increases in blood pressure and heart rate, suppression of growth, and peripheral vasculopathy; consistent "do not breastfeed while on therapy" language appears across other amphetamine products, strengthening the directive from a class-safety perspective [^113R1yyv] [^111zoF5V] [^111vbsRh] [^113pXK2f].

> But wait, what if the mother's clinical need for a stimulant is compelling and breastfeeding benefits are substantial; are there relatively safer pharmacologic alternatives within the stimulant class for lactation exposure? I need to check comparative lactation data. Methylphenidate labeling (e.g. Relexxii) reports lower measured infant exposures (RID roughly 0.16%–0.7%) with no reported adverse effects in the small published datasets, though, as with amphetamines, long-term neurodevelopmental effects remain unknown; if pharmacotherapy is essential during lactation, methylphenidate is often considered over amphetamines due to lower milk transfer, while acknowledging the paucity of robust long-term data and the need for infant monitoring for agitation, anorexia, and reduced weight gain [^111wgAUx].

> Let me think about counseling and monitoring, because even when labels advise against breastfeeding, real-world decisions sometimes require nuanced risk–benefit balancing. If, after shared decision-making, exposure occurs, I should confirm that families are counseled to use the lowest effective dose, to be vigilant for infant symptoms such as irritability, poor feeding, sleep disturbance, and inadequate weight gain, and to involve the pediatrician early for growth and cardiovascular monitoring; these general principles are consistent with lactation pharmacology guidance and clinical reviews emphasizing individualized assessment, infant age, dose minimization, and close follow-up when medication exposure via breast milk cannot be avoided [^113SeMoQ] [^111hFJzs] [^114UM8xV].

> Bottom line: Vyvanse is converted to dextroamphetamine, which appears in human milk with reported relative infant doses of about 2%–13.8% and milk-to-plasma ratios of 1.9–7.5; while no acute adverse events are reported in the limited cases, long-term neurodevelopmental effects are unknown, high doses may reduce milk supply, and the FDA advises that breastfeeding is not recommended during Vyvanse therapy; if stimulant therapy is indispensable during lactation, methylphenidate may offer lower infant exposure, though decisions should be individualized with careful pediatric monitoring and shared decision-making given the evidence gaps [^113R1yyv] [^111zoF5V] [^111vbsRh] [^113pXK2f] [^111wgAUx].

---

Yes, Vyvanse (lisdexamfetamine) is excreted into breast milk as its active metabolite, dextroamphetamine, with a **relative infant dose of 2–13.8%** of the maternal weight-adjusted dose and a milk/plasma ratio of 1.9–7.5 [^113R1yyv]. Although no adverse effects have been reported in breastfed infants, the FDA advises that **breastfeeding is not recommended** during Vyvanse treatment due to potential risks such as cardiovascular effects, growth suppression, and neurodevelopmental concerns [^111vbsRh].

---

## Pharmacokinetics of vyvanse and its active metabolite

Vyvanse is a **prodrug converted to dextroamphetamine**, which is responsible for its therapeutic and adverse effects [^113R1yyv]. The pharmacokinetic properties of dextroamphetamine influence its **transfer into breast milk**:

- **Molecular weight**: Low, facilitating transfer into breast milk [^113SeMoQ].

- **Lipid solubility**: High, promoting diffusion into breast milk [^115t7NuB].

- **Protein binding**: Moderate, allowing a significant fraction to diffuse into milk.

- **Half-life**: Approximately 10–13 hours, leading to sustained presence in maternal plasma and breast milk.

These properties collectively contribute to the **presence of dextroamphetamine in breast milk** and potential exposure to nursing infants [^114UM8xV].

---

## Evidence of vyvanse excretion into breast milk

Limited clinical data specifically address the excretion of Vyvanse into breast milk; however, available evidence indicates that dextroamphetamine, the active metabolite of Vyvanse, is **present in human milk**. According to the FDA label, the **relative infant dose** is 2% to 13.8% of the maternal weight-adjusted dosage, with a **milk/plasma ratio** of 1.9 to 7.5, indicating significant concentration in breast milk [^113R1yyv]. These findings are **consistent with other amphetamine-based medications**, such as Adderall XR [^113pXK2f] and Mydayis [^111vbsRh], which also report similar relative infant doses and milk/plasma ratios.

---

## Potential risks and adverse effects on breastfed infants

Although no specific adverse effects have been reported [^111zoF5V] in breastfed infants exposed to Vyvanse, **the FDA highlights several potential risks** [^113R1yyv] associated with amphetamine exposure through breast milk:

- **Cardiovascular effects**: Increased heart rate and blood pressure [^113R1yyv].

- **Growth suppression**: Potential interference with normal growth and development [^114Wi9kg].

- **Neurodevelopmental effects**: Long-term effects on infant neurodevelopment are unknown [^111vbsRh].

- **Peripheral vasculopathy**: Potential vascular complications [^115K8BAg].

Given these potential risks, the **FDA explicitly advises** against breastfeeding during Vyvanse treatment [^113R1yyv].

---

## Clinical guidelines and recommendations

Clinical guidelines emphasize that **breastfeeding is not recommended** during Vyvanse treatment [^113R1yyv] because of the potential for serious adverse reactions in nursing infants, including cardiovascular effects, growth suppression, and unknown neurodevelopmental risks [^114UM8xV]. When Vyvanse is essential, clinicians should **consider alternative medications** with lower risk profiles [^111wgAUx] and if continuation is necessary, carefully monitor the infant for adverse effects such as agitation, poor feeding, and growth suppression [^111hFJzs].

---

## Factors influencing vyvanse transfer into breast milk

Several **factors influence** the extent of Vyvanse transfer into breast milk:

- **Maternal dosage**: Higher maternal doses result in increased drug concentrations in breast milk [^113SeMoQ].

- **Timing of administration**: Breastfeeding shortly after maternal dosing increases infant exposure [^1161CZrc].

- **Infant age and metabolism**: Younger infants with immature metabolic systems are more susceptible to drug exposure and adverse effects [^114C7YVs].

- **Maternal metabolism**: Variability in maternal metabolism can influence drug levels in breast milk [^1129YUSB].

---

## Summary of key findings

| **Parameter** | **Findings** |
|-|-|
| Presence in breast milk | Yes, dextroamphetamine detected [^113R1yyv] |
| Relative infant dose | 2% to 13.8% of maternal dose [^113R1yyv] |
| Milk/plasma ratio | 1.9 to 7.5 [^113R1yyv] |
| Reported adverse effects | None reported, but potential risks exist [^111zoF5V] |
| FDA recommendation | Breastfeeding not recommended during Vyvanse treatment [^113R1yyv] |

---

Vyvanse is **excreted into breast milk** as dextroamphetamine, with a relative infant dose of 2% to 13.8% of the maternal dose [^113R1yyv]. Although no specific adverse effects have been reported, the FDA **advises against breastfeeding** during Vyvanse treatment due to potential risks such as cardiovascular effects, growth suppression, and unknown neurodevelopmental effects [^111vbsRh].

---

## References

### Vyvanse [^113R1yyv]. U.S. Food and Drug Administration (2023). High credibility.

Lisdexamfetamine is a pro-drug of dextroamphetamine. Based on limited case reports in published literature, amphetamine (d- or d, l-) is present in human milk, at relative infant doses of 2% to 13.8% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.9 and 7.5. There are no reports of adverse effects on the breastfed infant. Long-term neurodevelopmental effects on infants from amphetamine exposure are unknown. It is possible that large dosages of dextroamphetamine might interfere with milk production, especially in women whose lactation is not well established. Because of the potential for serious adverse reactions in nursing infants, including serious cardiovascular reactions, blood pressure and heart rate increase, suppression of growth, and peripheral vasculopathy, advise patients that breastfeeding is not recommended during treatment with Vyvanse.

- **Attention deficit hyperactivity disorder (ADHD)**: Safety and effectiveness of Vyvanse have been established in pediatric patients with ADHD ages 6 to 17 years [see Dosage and Administration (2.3), Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical Studies (14.1)]. Safety and effectiveness of Vyvanse have not been established in pediatric patients below the age of 6 years. Safety and efficacy of Vyvanse were evaluated in a double-blind, randomized, parallel-group, placebo-controlled, fixed-dose study in pediatric patients ages 4 to 5 years with ADHD, followed by a 1-year open-label extension study. In these studies, patients experienced elevated rates of adverse reactions, including weight loss.

---

### SPL drug information for lisdexamfetamine dimesylate [^114CJzws]. U.S. Food and Drug Administration. High credibility.

Regarding the use of lisdexamfetamine dimesylate PO (also known as Vyvanse) in patients with GFR < 15 mL/min, the maximal dose is 30 mg. Do not exceed a frequency of once daily.

---

### Improving safe and effective use of drugs in pregnancy and lactation: Workshop summary [^1129YUSB]. American Journal of Perinatology (2017). Low credibility.

There is limited information on most drugs used by breastfeeding women, which poses challenges for women and their providers. Consequently, many providers recommend stopping a medication based on theoretical concerns about its safety for the neonate, and this may lead to inadequately treated maternal disease.

The information needed to make decisions about medications and breastfeeding includes knowledge of the need for the drug, the excretion of the drug into breast milk, the extent of oral absorption of the drug by the neonate, the potential adverse effects on the neonate, and the potential effect of the drug on lactation. Additionally, the infant's age is relevant and should be considered, as adverse events are rarer in infants older than six months.

As in pregnancy, the biochemical properties of a given drug are important. Elements such as drug ionization, molecular weight, volume of distribution, lipid solubility, and protein binding may influence how much of the drug is excreted into breast milk. Furthermore, the half-life of the drug and its oral bioavailability will influence how much is absorbed by the neonate.

One example of these complexities includes emerging data demonstrating that there are specific patient genotypes that influence the toxicity of given drugs. Stover and Davis suggest that this area of pharmacogenomics holds promise in understanding how neonates with in-utero exposure to opioids may have different withdrawal patterns based on specific polymorphisms.

---

### Relexxii [^111wgAUx]. U.S. Food and Drug Administration (2024). High credibility.

- **Lactation**:

- **Risk summary**: Limited published literature, based on breast milk sampling from five mothers, reports that methylphenidate is present in human milk. This resulted in infant doses of 0.16% to 0.7% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.1 and 2.7. There are no reports of adverse effects on the breastfed infant and no effects on milk production. However, long-term neurodevelopmental effects on infants from CNS stimulant exposure are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Relexxii and any potential adverse effects on the breastfed infant from Relexxii or from the underlying maternal condition.

- **Clinical considerations**: Monitor breastfeeding infants for adverse reactions, such as agitation, anorexia, and reduced weight gain.

- **Pediatric use**:

The safety and effectiveness of Relexxii for the treatment of ADHD have been established in pediatric patients aged 6 to 17 years. However, the safety and effectiveness in pediatric patients less than 6 years have not been established. The long-term efficacy of methylphenidate in pediatric patients has not been established either.

- **Long-term suppression of growth**: Growth should be monitored during treatment with stimulants, including Relexxii. Pediatric patients who are not growing or gaining weight as expected may need to have their treatment interrupted [see Warnings and Precautions (5.7) and Adverse Reactions (6.1)].

- **Juvenile animal toxicity data**: In the study conducted in young rats, methylphenidate…

---

### FDA drug labeling for pregnancy and lactation drug safety monitoring systems [^111wJywQ]. Seminars in Perinatology (2015). Low credibility.

The product label required by the FDA for every drug approved for marketing in the US is a legal document that originates with the company that wants to market the drug, but it must be approved by the FDA. Despite the recognized limitations of registries, the FDA's new labeling rule, effective from July 1, 2015, has prioritized the data available from post-marketing surveillance in the new label. For this information to be maximally useful to both providers and consumers, providers must refer as many exposed consumers as possible to the registries, preferably prior to knowledge of the outcomes of the pregnancies. Consumers need to cooperate with the registries to share their health information in as much detail as possible with the registries. It will take years to accumulate a meaningful quantity of information in many of the registries, but they promise to be our best hope for useful counseling information in the future.

---

### Tauvid [^112dWuDt]. U.S. Food and Drug Administration (2024). High credibility.

- **Use in specific populations**:
	- **Lactation**: Advise a lactating woman to avoid breastfeeding for 4 hours after Tauvid administration to minimize radiation exposure to the breastfed infant.

- **Pregnancy**:
	- **Risk summary**: All radiopharmaceuticals, including Tauvid, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of radiation dose. Advise a pregnant woman of the potential risks of fetal exposure to radiation doses with administration of Tauvid. Tauvid is not likely to be used in females of reproductive age. There are no available data on Tauvid use in pregnant women. No animal reproduction studies using flortaucipir F 18 have been conducted to evaluate its effect on female reproduction and embryo-fetal development. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

- **Lactation**:
	- **Risk summary**: There are no data on the presence of flortaucipir F 18 in human milk, or its effects on the breastfed infant or milk production. Lactation studies have not been conducted in animals. Advise a lactating woman to avoid breastfeeding for 4 hours after Tauvid administration.

- **Pediatric use**: The safety and effectiveness of Tauvid in pediatric patients have not been established.

---

### SPL drug information for lisdexamfetamine dimesylate [^111bbzpy]. U.S. Food and Drug Administration. High credibility.

Regarding the use of lisdexamfetamine dimesylate PO (also known as Vyvanse) in patients with chronic liver disease, any severity, use is acceptable, and no dose adjustment is required.

---

### Study protocol: a double-blind, placebo-controlled trial examining the effect of domperidone on the composition of breast milk [^114orzZh]. BMC Pregnancy and Childbirth (2006). Low credibility.

Domperidone, a drug that enhances upper gastric motility, is an anti-dopaminergic medication that also elevates prolactin levels. It has been shown to safely increase the milk supply of lactating women. At the time of writing, researchers have analyzed the effects of domperidone on lactating women with respect to the quantity of their milk production, adverse effects, and drug levels in the breast milk. However, the effect of domperidone on the macronutrient composition of breast milk has not been studied, and guidelines for fortification of human milk for premature infants do not distinguish between those women using or those not using domperidone. The purpose of this study is to evaluate the effect of domperidone (given to lactating mothers of very preterm infants) on the macronutrient composition of breast milk.

- **Methods/design**: Mothers of infants delivered at less than 31 weeks gestation, who are at least 3 weeks postpartum and experiencing lactational failure despite non-pharmacological interventions, will be randomized to receive domperidone (10 mg three times daily) or placebo for a 14-day period. Breast milk samples will be obtained the day prior to beginning treatment and on days 4, 7, and 14. The macronutrient (protein, fat, carbohydrate, and energy) and macromineral content (calcium, phosphorus, and sodium) will be analyzed and compared between the two groups. Additional outcome measures will include milk volumes, serum prolactin levels (measured on days 0, 4, and 10), daily infant weights, and breastfeeding rates at 2 weeks post-study completion and at discharge.

---

### Modeling drug passage into human milk [^113SeMoQ]. Clinical Pharmacology and Therapeutics (2016). Low credibility.

Breastfeeding has positive health consequences for both the breastfed infant and the nursing mother. Although information on drug use during lactation is available through sites such as LactMed, available information is often incomplete. Unlike pregnancy, in which large numbers of pregnant women need to be studied to assure safety, measurement of drug concentrations in breast milk from a relatively few subjects can provide valuable information to assess drug safety. This article reviews methods of measuring and predicting drug passage into breast milk.

---

### Pattern of uptake and excretion of (18)f-fdg in the lactating breast [^111hbeX9]. Journal of Nuclear Medicine (2001). Low credibility.

Excretion of radiopharmaceuticals into breast milk poses a potential risk to infants, and clear recommendations regarding interruption times are required. There are few data available regarding the impact of (18)F-FDG on this issue. With increasing use of PET for oncologic imaging and its potential advantages to nursing mothers due to its short physical half-life, compared with other commonly used tumor imaging agents such as (67)Ga and (201)Tl, evaluation of the excretion pattern of this agent in breast milk is important.

- **Methods**: We have evaluated the uptake of FDG in the breasts of 7 women. Six of these women were lactating, and one was in early postpartum but had not commenced breast-feeding. Milk samples were obtained from four of the lactating women, including serial samples from one.

- **Results**: Significantly increased breast uptake was identified in all lactating breasts but not in one breast consistently refused by the nursing infant or in the woman who had not begun breast-feeding after the delivery of her child. No qualitative change or semiquantitative estimate of radiotracer uptake in the breast was seen after the expression of breast milk. Decay-corrected activity measurable in breast milk ranged from 5.54 to 19.3 Bq/mL/MBq injected. Using a standard model of breast-feeding, the calculated maximum cumulative dose to the infant, 0.085 mSv with no interruption of breast-feeding, is well below the recommended limit of 1 mSv.

- **Conclusion**: High uptake of FDG in the lactating breast appears to be related to suckling. There is, however, little secretion of activity into breast milk.

---

### Study protocol: a double blind placebo controlled trial examining the effect of domperidone on the composition of breast milk [NCT00308334] [^116H9Vw8]. BMC Pregnancy and Childbirth (2006). Low credibility.

The initial preparation time for this study will be two weeks. During this period, information will be provided to the staff of the Neonatal Intensive Care Unit regarding the study protocol. Approximately 60 infants less than 31 weeks gestation are admitted to IWK yearly, with 20–25 percent of these being multiples. Breast-feeding initiation rates in our nursery are 80–85 percent. If half of these women experience difficulty with breast milk supply, 20–23 women a year will be eligible for the study. Recruitment rates are expected to be greater than 90 percent.

Subject accrual and data collection will extend over 24 months. An additional four months will be required to analyze the data and prepare a manuscript. The study results are intended to be widely disseminated through conference proceedings and peer-reviewed publications. The total duration of the study is expected to be 28 months.

---

### Vyvanse [^116JBXuF]. U.S. Food and Drug Administration (2023). High credibility.

- **Absorption**: Following single-dose oral administration of Vyvanse capsule (30 mg, 50 mg, or 70 mg) in patients ages 6 to 12 years with ADHD under fasted conditions, Tmax of lisdexamfetamine and dextroamphetamine was reached at approximately 1 hour and 3.5 hours post dose, respectively. Weight/dose normalized AUC and Cmax values were the same in pediatric patients ages 6 to 12 years as in adults following single doses of 30 mg to 70 mg Vyvanse capsule.

- **Effect of food on capsule formulation**: Neither food (a high-fat meal or yogurt) nor orange juice affects the observed AUC and Cmax of dextroamphetamine in healthy adults after single-dose oral administration of 70 mg of Vyvanse capsules. Food prolongs Tmax by approximately 1 hour (from 3.8 hours at a fasted state to 4.7 hours following a high-fat meal or 4.2 hours with yogurt). After an 8-hour fast, the AUC for dextroamphetamine following oral administration of lisdexamfetamine dimesylate in solution and as intact capsules were equivalent.

- **Chewable tablet formulation**: After a single-dose administration of 60 mg Vyvanse chewable tablet in healthy subjects under fasted conditions, Tmax of lisdexamfetamine and dextroamphetamine was reached at approximately 1 hour and 4.4 hours post dose, respectively. Compared to the 60 mg Vyvanse capsule, exposure (Cmax and AUC) to lisdexamfetamine was about 15% lower. The exposure (Cmax and AUCinf) of dextroamphetamine is similar between Vyvanse chewable tablet and Vyvanse capsule.

- **Effect of food on tablet formulation**: Administration of 60 mg Vyvanse chewable tablet with food (a high-fat meal) prolongs Tmax similar to the capsule formulation, although more detailed data is omitted from this section.

---

### Lisdexamfetamine maintenance treatment for binge-eating disorder following successful treatments: Randomized double-blind placebo-controlled trial [^114F2xea]. Psychological Medicine (2024). High credibility.

This single-site RCT was approved by the Yale Institutional Review Board and included a data safety and monitoring plan with a physician safety monitor. Participants provided written informed consent.

- **Participants**: Participants for this controlled maintenance trial were eligible if they were categorized as 'responders' following initial acute 12-week treatments with LDX alone or with CBT + LDX in an RCT for BED with obesity (Grilo et al.). When participants enrolled in the treatment study, they were informed and they consented to two treatment stages; the acute treatment stage and a second stage that would test pharmacotherapy maintenance if they responded to the initial treatments comprising pharmacotherapy. Participation in this maintenance treatment study was anticipated when participants consented to the 2-stage (initial acute 'Stage 1' plus maintenance 'Stage 2') treatments without an opt-out, unless medically contraindicated.

- **Eligibility requirements**: Eligibility for the acute trial required meeting DSM-5 (APA) BED criteria, ages 18–64 years old, and a body mass index (BMI; kg/m²) ≥ 30.0 and ≤ 50.0 (or ≥ 27.0 with obesity-related comorbidity). Exclusion criteria included clinical issues that required alternative treatments or represented contraindications to lisdexamfetamine, including evidence-based treatment for eating/weight disorders, taking contraindicated medications (e.g. opiates, MAOIs, NDRIs, and stimulants; SSRIs and strong inhibitors of CYP2D6 were considered).

---

### SPL drug information for lisdexamfetamine dimesylate [^117WsiMc]. U.S. Food and Drug Administration. High credibility.

Lisdexamfetamine dimesylate, also known as Vyvanse, is labeled for the following indications:

- **Treatment of binge eating disorder**: This includes moderate-to-severe cases in adults.
- **Treatment of attention deficit hyperactivity disorder**: Applicable to adults suffering from this condition.

---

### Postpartum depression: A role for psychedelics [^11549aP8]. Journal of Psychopharmacology (2022). Low credibility.

Molecular size and lipid solubility also determine drug diffusion into breast milk. Low molecular weight drugs, such as psilocin, can cross readily into breast milk. Psilocin is more lipid-soluble than psilocybin, suggesting that it can diffuse readily into breast milk. Psilocybin can transiently increase prolactin during peak effects, but levels return to baseline 5 hours after oral administration, leaving no effect on breast milk production.

Another factor determining the risk of infant adverse effects through drug exposure in breast milk is the age of the infant. About 78% of drug-related adverse effects occur in breastfeeding infants aged under 2 months, and only 4% of adverse effects are noted in infants older than 6 months.

The pharmacokinetics of psilocybin and psilocin in breastmilk are yet to be examined in trials. However, knowledge can be extrapolated to indicate that the lipophilicity of psilocin and its low molecular weight may allow for transfer into breast milk, while its acidity and binding to serum albumin suggest it is less likely to pass into breast milk.

In the absence of pharmacokinetic evidence for psilocin in breast milk, maternal plasma concentration of psilocin may be the most useful indicator of breast milk concentration. Evidence suggests that almost all psilocin will be eliminated by 48 hours after administration. Including women beyond 6 months postpartum and advising abstention from breastfeeding for a 48-hour period after psilocybin administration may reduce potential risks to the infant in future clinical trials.

---

### Updated, web-based nutrition management guideline for PKU: An evidence and consensus based approach [^111ZyY4c]. Molecular Genetics and Metabolism (2016). High credibility.

Regarding specific circumstances for phenylketonuria, particularly with respect to breastfeeding, the GMDI/SERC 2016 guidelines recommend encouraging the use of breast milk, when possible, either from direct breastfeeding or the use of expressed breast milk, as the source of phenylalanine (and intact protein) in infants.

---

### Adzenys XR-ODT [^111zoF5V]. U.S. Food and Drug Administration (2025). High credibility.

- **Lactation**:

Based on limited case reports in published literature, amphetamine (d- or d, l-) is present in human milk at relative infant doses of 2% to 13.8% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.9 and 7.5. There are no reports of adverse effects on the breastfed infant. Long-term neurodevelopmental effects on infants from amphetamine exposure are unknown. It is possible that large dosages of amphetamine might interfere with milk production, especially in women whose lactation is not well established. Because of the potential for serious adverse reactions in nursing infants, advise patients that breastfeeding is not recommended during treatment with Adzenys XR-ODT.

- **Pregnancy**:

There is a pregnancy exposure registry that monitors outcomes in women exposed to ADHD medications, including Adzenys XR-ODT, during pregnancy. Healthcare providers are encouraged to advise patients to register by contacting the National Pregnancy Registry for ADHD Medication at 1–866–961–2388 or online at www.womensmentalhealth.org/pregnancyregistry.

Available data from epidemiologic studies and postmarketing reports on the use of amphetamine in pregnant women over decades have not identified a drug-associated risk of major birth defects or miscarriage. However, neonates exposed to amphetamine in utero are at risk for withdrawal symptoms following delivery. Adverse pregnancy outcomes, including premature delivery and low birth weight, have been seen in infants born to mothers taking amphetamines.

---

### Excretion of radionuclides in human breast milk after nuclear medicine examinations. Biokinetic and dosimetric data and recommendations on breastfeeding interruption [^114jXeJt]. European Journal of Nuclear Medicine and Molecular Imaging (2016). High credibility.

The purpose of this study was to review early recommendations and propose guidelines for breastfeeding interruption after the administration of radiopharmaceuticals, based on additional biokinetic and dosimetric data.

- **Methods**: Activity concentrations in breast milk from 53 breastfeeding patients were determined. The milk was collected at various times after administration of 16 different radiopharmaceuticals. The fraction of the activity administered to the mother excreted in the breast milk, the absorbed doses to various organs and tissues, and the effective dose to the infant were estimated.

- **Results**: The fraction of the administered activity excreted per milliliter of milk varied widely from 10⁻¹⁰ to 10⁻³ MBq/MBq administered. For (99m)Tc-labelled radiopharmaceuticals, the total fraction of the administered activity excreted in the milk varied from 0.0057% for (99m)Tc-labelled red blood cells (RBC) to 19% for (99m)Tc-pertechnetate. The effective dose to an infant per unit activity administered to the mother ranged from 6.7×10⁻⁶ mSv/MBq for (99m)Tc-labelled RBC to 3.6×10⁻² mSv/MBq for (99m)Tc-pertechnetate. For other radiopharmaceuticals, the total fraction of administered activity excreted in the milk varied from 0.018% ((51)Cr-EDTA) to 48% ((131)I-NaI). The effective dose ranged from 5.6×10⁻⁵ mSv/MBq ((51)Cr-EDTA) to 106 mSv/MBq ((131)I-NaI).

- **Conclusions**: Based on an effective dose limit of 1 mSv to the infant and a typical administered activity, we recommend cessation of breastfeeding for (131)I-NaI and interruption of feeding for 12 hours for (125)I-iodo.

---

### Study protocol: A double blind placebo controlled trial examining the effect of domperidone on the composition of breast milk [^1162XtGS]. BMC Pregnancy and Childbirth (2006). Low credibility.

The macronutrient composition (protein, fat, and calories) of human breast milk will be significantly altered by the administration of domperidone.

---

### Study protocol: A double blind placebo controlled trial examining the effect of domperidone on the composition of breast milk [^1116db3E]. BMC Pregnancy and Childbirth (2006). Low credibility.

Potential risks to the safety of participants involved in the study:

- **Potential side effects of medication**: Side effects associated with the use of oral domperidone are extremely uncommon. Reported side effects include dry mouth, transient skin rash or itching, headache, thirst, abdominal cramps, diarrhea, drowsiness, and nervousness. These side effects have generally been associated with high dosages of the medication. Symptoms are usually minor, and all symptoms disappear following discontinuation of the medication.

	- Domperidone is highly metabolized by CYP3A4 in the liver, and drug interactions related to its inhibition are expected to occur. Cimetidine, ranitidine, famotidine, and nizatidine may interfere with domperidone's bioavailability and should not be co-administered. Medications such as haloperidol and lithium, when taken at the same time as domperidone, may cause exaggerated central nervous system symptoms. Therefore, subjects who satisfy eligibility criteria will not be invited to participate in this study if they are taking any of these medications.

	- Low levels of domperidone are excreted in human breast milk. There are no reported cases of side effects in infants. As previously mentioned, the Canadian and American Academy of Pediatrics have approved its use in breastfeeding mothers.

- **Confidentiality**: Participant data collected during this trial will be kept confidential and locked in a secure office area. Study staff will have access to the data as well as participants' medical records.

---

### Infant factors that impact the ecology of human milk secretion and composition-a report from "Breastmilk Ecology: Genesis of Infant Nutrition (BEGIN)" Working Group 3 [^115XfoAF]. The American Journal of Clinical Nutrition (2023). Low credibility.

Transmission of xenobiotics to human milk and consequences of infant exposure: As addressed in the WG 1 report, important determinants of the concentration of a substance in human milk are its concentration in the lactating parent's plasma (nonprotein-bound) and the interfeed and intrafeed blood flow to the breast. This applies to xenobiotics, which include environmental agents such as medications, recreational and illicit drugs, pesticides, and endocrine-disrupting chemicals. For alcohol and tobacco, infants can detect flavor changes in human milk, and early experiences with the sensory properties of these recreational drugs impact subsequent behavioral responses during childhood. Whether similar flavor changes occur following cannabis or other drugs is currently unknown.

Extensive evidence indicates that use of alcohol, tobacco, and cannabis by a lactating parent, alone or in combination, impacts the developing brain and is linked to adverse pregnancy outcomes, adverse outcomes in infants and children, and adverse academic performance and drug misuse in adolescents. The contributions of drug exposure via human milk alone and how breastfeeding may protect against such exposures are often confounded by the reality of prenatal exposure and the fact that polydrug use is common. Many parents who use these drugs have partners or other household members who also use drugs, thereby increasing the likelihood of infants' secondhand exposure to tobacco and cannabis. The following sections highlight the challenge of distinguishing the direct effects of the drug on the parental lactation.

---

### Percocet [^112NSbNR]. U.S. Food and Drug Administration (2024). High credibility.

Available data from lactation studies indicate that oxycodone is present in breast milk. Doses of less than 60 mg/day of the immediate-release formulation are unlikely to result in clinically relevant exposures in breastfed infants. A pharmacokinetics study utilizing opportunistic sampling of 76 lactating women receiving oxycodone immediate-release products for postpartum pain management showed that oxycodone concentrates in breast milk with an average milk-to-plasma ratio of 3.2. The relative infant dose was low, approximately 1.3% of a weight-adjusted maternal dose [see Data].

In the same study, among the 70 infants exposed to oxycodone in breast milk, no adverse events were attributed to oxycodone. However, based on known adverse effects in adults, infants should be monitored for signs of excess sedation and respiratory depression [see Clinical Considerations]. There are no data on the effects of oxycodone on milk production.

Acetaminophen is also excreted in breast milk in low concentrations. The developmental and health benefits of breastfeeding should be considered, along with the mother's clinical need for Percocet and any potential adverse effects on the breastfed infant from Percocet or from the underlying maternal condition.

Infants exposed to Percocet through breast milk should be monitored for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped or when breastfeeding is stopped.

---

### Maternal medication, drug use, and breastfeeding [^111hFJzs]. Pediatric Clinics of North America (2013). Low credibility.

This article reviews the necessary skills required for clinicians to make informed decisions about the use of medications in women who are breastfeeding. Even without specific data on certain medications, this review of kinetic principles, mechanisms of medication entry into breast milk, and important infant factors can aid in clinical decision-making. In addition, common medical conditions and suitable treatments for women who are breastfeeding, such as depression, hypertension, and infections, are also reviewed.

---

### Mother and child: Medication use in pregnancy and lactation [^113dwrQ8]. Clinical Pharmacology and Therapeutics (2016). Low credibility.

Pregnancy and breastfeeding pose a unique challenge to drug development and clinical application. In addition to concerns over drug toxicity to the fetus in utero and infants through breastfeeding, there are also alterations of pharmacokinetics in these women that require careful attention. How do we address the overall lack of drug efficacy and toxicity information for pregnant and breastfeeding women?

---

### SPL drug information for lisdexamfetamine dimesylate [^117AvHD9]. U.S. Food and Drug Administration. High credibility.

The dosage of lisdexamfetamine dimesylate administered orally for the treatment of attention deficit hyperactivity disorder in adults is as follows:

- **Maintenance**: 30 mg taken orally every morning.
- **Maximum**: 70 mg per day.

---

### SPL drug information for lisdexamfetamine dimesylate [^116gNAwC]. U.S. Food and Drug Administration. High credibility.

Regarding the use of lisdexamfetamine dimesylate PO (also known as Vyvanse) in patients with GFR > 30 mL/min, use is acceptable. No dose adjustment is required.

---

### Commentary: Tolvaptan for autosomal dominant polycystic kidney disease (ADPKD) - an update [^115iu8Hk]. BMC Nephrology (2025). Low credibility.

It is not known whether tolvaptan is excreted in human milk, or what effects it may have on the breast-fed infant or milk production. Animal studies have shown the excretion of tolvaptan in milk. Otsuka advises against breastfeeding while taking tolvaptan and recommends delaying breastfeeding for four weeks after stopping the medication.

---

### Transfer of drugs and other chemicals into human milk [^115t7NuB]. Pediatrics (2001). Low credibility.

The American Academy of Pediatrics emphasizes the importance of increasing breastfeeding rates in the United States. A common reason for the cessation of breastfeeding is the mother's use of medication, often accompanied by a physician's advice to stop nursing. Such advice may not always be warranted. This statement aims to provide pediatricians, obstetricians, and family physicians with data, when available, regarding the excretion of drugs into human milk. Most drugs that are likely to be prescribed to nursing mothers should not affect milk supply or the well-being of the infant. This information is crucial not only to protect nursing infants from adverse effects of maternal medication but also to enable effective pharmacologic treatment for breastfeeding mothers. Nicotine, psychotropic drugs, and silicone implants are three significant topics reviewed in this statement.

---

### Lexapro [^116hArZw]. U.S. Food and Drug Administration (2023). High credibility.

Data from the published literature report the presence of escitalopram and desmethylescitalopram in human milk. There are reports of excessive sedation, restlessness, agitation, poor feeding, and poor weight gain in infants exposed to escitalopram through breast milk. There are no data on the effects of escitalopram or its metabolites on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Lexapro and any potential adverse effects on the breastfed child from Lexapro or from the underlying maternal condition.

- **Clinical considerations**: Infants exposed to Lexapro should be monitored for excess sedation, restlessness, agitation, poor feeding, and poor weight gain.

- **Data**: A study of 8 nursing mothers on escitalopram with daily doses of 10–20 mg/day showed that exclusively breast-fed infants receive approximately 3.9% of the maternal weight-adjusted dose of escitalopram and 1.7% of the maternal weight-adjusted dose of desmethylescitalopram.

---

### Mydayis [^111vbsRh]. U.S. Food and Drug Administration (2025). High credibility.

- **Lactation**:
	- Based on limited case reports in published literature, amphetamine (d- or d, l-) is present in human milk, at relative infant doses of 2 to 13.8% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.9 and 7.5. There are no reports of adverse effects on the breastfed infant. Long-term neurodevelopmental effects on infants from amphetamine exposure are unknown. It is possible that large dosages of dextroamphetamine might interfere with milk production, especially in women whose lactation is not well established. Because of the potential for serious adverse reactions in nursing infants, including serious cardiovascular reactions, blood pressure and heart rate increase, suppression of growth, and peripheral vasculopathy, advise patients that breastfeeding is not recommended during treatment with Mydayis.

- **Pediatric use**:
	- The safety and effectiveness of Mydayis in pediatric patients with ADHD ages 13 to 17 years have been established in two placebo-controlled clinical studies [see Adverse Reactions (6.1), Clinical Pharmacology (12.3), Clinical Studies (14)]. The safety and effectiveness of Mydayis have not been established in pediatric patients ages 12 years and younger.

	- Mydayis has been studied for the treatment of ADHD in pediatric patients aged 6 to 12 years in two placebo-controlled safety and efficacy trials. In the first trial, pediatric patients aged 6 to 12 years experienced higher rates of adverse reactions in some cases compared to patients 13 years and older, including higher rates of insomnia (30% vs. 8%) and appetite suppression.

---

### Symbyax [^114hsgen]. U.S. Food and Drug Administration (2025). High credibility.

Data from published literature report the presence of olanzapine, fluoxetine, and norfluoxetine in human milk. There are reports of excess sedation, irritability, poor feeding, and extrapyramidal symptoms (tremors and abnormal muscle movements) in infants exposed to olanzapine through breast milk, and reports of agitation, irritability, poor feeding, and poor weight gain in infants exposed to fluoxetine through breast milk. There is no information on the effects of olanzapine or fluoxetine and their metabolites on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for SYMBYAX and any potential adverse effects on the breastfed child from SYMBYAX or the underlying maternal condition.

- **Clinical considerations**: Infants exposed to SYMBYAX should be monitored for agitation, irritability, poor feeding, poor weight gain, excess sedation, and extrapyramidal symptoms (tremors and abnormal muscle movements).

- **Data**: A study of nineteen nursing mothers on fluoxetine with daily doses of 10–60 mg showed that fluoxetine was detectable in 30% of nursing infant sera (range: 1 to 84 ng/mL), whereas norfluoxetine was found in 85% (range: < 1 to 265 ng/mL).

- **Infertility: Females**: Based on the pharmacologic action of olanzapine (dopamine D2 receptor blockade), treatment with SYMBYAX may result in an increase in serum prolactin levels, which may lead to a reversible reduction in fertility in females.

---

### A review of adverse reactions in infants from medications in breastmilk [^1116vYDb]. Clinical Pediatrics (2016). Low credibility.

The types and rates of adverse drug reactions experienced by breastfed infants whose mothers are taking medications have not been well defined. This article reviews the literature on adverse drug reactions in infants since a previous review in 2002. Case reports and studies of adverse drug reactions in breastfed infants whose mothers were taking prescribed or over-the-counter medication were selected. Fifty-three case reports and 16 studies were located. Serious acute adverse drug reactions from drugs in breastmilk appear to be uncommon.

Infants under 2 months of age, especially those under 1 month, appear to be most susceptible. Similar to previous reviews, free iodine, opioids, and the simultaneous use of multiple central nervous system drugs were identified as drugs of concern. A few narrowly focused studies are now available on the long-term effects of maternal drug therapy on breastfed infants, and they are mostly reassuring.

---

### Effexor XR [^1112MQ7B]. U.S. Food and Drug Administration (2023). High credibility.

- **Lactation: Risk summary**: Data from published literature report the presence of venlafaxine and its active metabolite in human milk and have not shown adverse reactions in breastfed infants. There are no data on the effects of venlafaxine on milk production.

	- The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Effexor XR and any potential adverse effects on the breastfed child from Effexor XR or from the underlying maternal condition.

- **Data**: In a lactation study conducted in 11 breastfeeding women (at a mean of 20.1 months postpartum) who were taking a mean daily dose of 194.3 mg of venlafaxine, and in a lactation study conducted in 6 breastfeeding women who were taking a daily dose of 225 mg to 300 mg of venlafaxine (at a mean of 7 months postpartum), the estimated mean relative infant dose was 8.1% and 6.4% based on the sum of venlafaxine and its major metabolite, desvenlafaxine. No adverse reactions were seen in the infants.

---

### Adverse drug reactions in breastfed infants: Less than imagined [^114C7YVs]. Clinical Pediatrics (2003). Low credibility.

Medication use during breastfeeding often shortens the duration of breastfeeding due to overly cautious information provided by healthcare providers. No comprehensive review of the literature on infant adverse reactions from drugs in breastmilk has been published. All published studies and case reports on adverse events in infants caused by medications (excluding drugs of abuse) in breastmilk were identified and analyzed. Of 100 case reports evaluated, none were considered to be "definite" using a standard ranking scale; 47% were "probable" and 53% were "possible". Drugs with central nervous system activity accounted for half of all reports. All three reported fatalities involved central nervous system depressants, but each had extenuating circumstances. At least 63% of reported cases were in neonates, and 78% were in infants 2 months or younger. Only 4% of adverse reactions occurred in infants older than 6 months of age. Published studies expand on and generally reinforce the analysis of case reports. By taking a few simple precautions in drug selection and considering the infant's age, breastfeeding rarely needs to be discouraged or discontinued when a mother requires drug therapy.

---

### Medications in the breast-feeding mother [^1161CZrc]. American Family Physician (2001). Low credibility.

Prescribing medications for a breast-feeding mother requires weighing the benefits of medication use for the mother against the risk of not breast-feeding the infant or the potential risk of exposing the infant to medications. A drug that is safe for use during pregnancy may not be safe for the nursing infant. The transfer of medications into breast milk depends on a concentration gradient that allows passive diffusion of non-ionized, non-protein-bound drugs.

The infant's medication exposure can be limited by prescribing medications to the breast-feeding mother that are poorly absorbed orally, by avoiding breast-feeding during times of peak maternal serum drug concentration, and by prescribing topical therapy when possible. Mothers of premature or otherwise compromised infants may require altered dosing to avoid drug accumulation and toxicity in these infants. The most accurate and up-to-date sources of information, including internet resources and telephone consultations, should be used.

---

### Study protocol: a double blind placebo controlled trial examining the effect of domperidone on the composition of breast milk [^115qU73k]. BMC Pregnancy and Childbirth (2006). Low credibility.

- **Allocation of participants to the trial groups**: Eligible and consenting women will be randomized in blocks of four. Pharmacy staff will randomly assign mothers, using a computer-based code, to receive either domperidone, 10 mg orally three times daily, or a placebo for a two-week period. Mothers of infants > 3 but < 4 weeks postpartum will be randomized separately from those ≥ 4 weeks postpartum to ensure identical proportions within the domperidone and placebo groups, meaning randomizations will be stratified by postpartum duration at study entry. Participants will receive their two-week drug or placebo supply following enrollment. They will be provided with instructions related to self-administration and asked to return the medication vial and any unused medication at the completion of the two-week period. The study nurse/investigators will maintain close contact with the mothers and review the medication instructions on study days 4, 7, and 14.

- **Figure 1**: Allocation of participants to the trial groups.

---

### Venlafaxine in human breast milk and nursing infant plasma: determination of exposure [^116S79Vv]. The Journal of Clinical Psychiatry (2009). Low credibility.

Use of venlafaxine during pregnancy has increased over the past decade, alongside accumulating reproductive safety data. However, systematic data on venlafaxine during lactation remain sparse. This study characterizes the level and determinants of venlafaxine and desvenlafaxine concentrations in breast milk and nursing infant plasma.

- **Method**: Women participating in a prospective investigation of perinatal pharmacokinetics from January 2001 through July 2006, who were treated with venlafaxine and chose to continue during lactation, were included in the analysis. Breast milk samples were collected via breast pump from foremilk to hindmilk from a single breast to determine the excretion gradient. Serial samples were collected over 24 hours to determine the time course of excretion. Paired maternal/infant plasma samples were also collected. Venlafaxine and desvenlafaxine concentrations were determined using high-performance liquid chromatography with ultraviolet detection. Statistical analyses of breast milk and infant plasma concentrations and their determinants were conducted.

- **Results**: Thirteen women and their nursing infants participated, providing 106 breast milk samples. The mean milk/plasma ratio was 275.3% (95% CI = 144.8% to 405.7%). There were statistically significant time courses of excretion for venlafaxine (R = 0.36, F = 6.82, P < .02), desvenlafaxine (R = 0.48, F = 4.41, P < .009), and combined venlafaxine/desvenlafaxine (R = 0.51, F = 5.16, P < .004), with the highest venlafaxine and desvenlafaxine concentrations observed.

---

### Ocella [^115EMgyi]. U.S. Food and Drug Administration (2023). High credibility.

Lactation

- **Risk summary**: DRSP is present in human milk. After a single oral administration of 3 mg DRSP/0.03 mg EE tablets, DRSP concentration in breast milk over the 24-hour period ranged from 1.4 to 7.0 ng/mL, with a mean ± standard deviation value of 3.7 ± 1.9 ng/mL. The estimated mean infant dose was 0.003 mg/day, which is about 0.1% of the maternal dose (see Data). There is limited information on the effects of Ocella on the breast-fed infant. CHCs can reduce milk production in breastfeeding females. This reduction can occur at any time but is less likely to occur once breastfeeding is well-established. When possible, advise the nursing female to use other methods of contraception until she discontinues breastfeeding [see also Dosage and Administration (2.2)].

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Ocella and any potential adverse effects on the breast-fed child from Ocella or from the underlying maternal condition.

- **Data**

	- **Human data**: An open-label study evaluated the degree of DRSP transfer into milk within 72 hours following a single oral administration of 3 mg DRSP/0.03 mg EE tablets to 6 healthy lactating women who were 1 week to 3 months postpartum. DRSP was present in breast milk with a mean Cmax of 13.5 ng/mL, while the mean Cmax in serum of lactating women was 30.8 ng/mL. The DRSP concentration in breast milk over the 24-hour period following dosing ranged from 1.4 to 7.0 ng/mL, with a mean ± standard deviation value of 3.7 ± 1.9 ng/mL. Based on single dose data, the maximal daily infant exposure was calculated.

---

### Imitrex [^114wbrQ8]. U.S. Food and Drug Administration (2024). High credibility.

Sumatriptan is excreted in human milk following subcutaneous administration (see Data). There is no information regarding sumatriptan concentrations in milk from lactating women following administration of Imitrex tablets. There are no data on the effects of sumatriptan on the breastfed infant or the effects on milk production.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Imitrex tablets and any potential adverse effects on the breastfed infant from sumatriptan or from the underlying maternal condition.

- **Clinical considerations**: Infant exposure to sumatriptan can be minimized by avoiding breastfeeding for 12 hours after treatment with Imitrex tablets.

- **Data**: Following subcutaneous administration of a 6-mg dose of Imitrex injection in 5 lactating volunteers, sumatriptan was present in milk.

---

### SPL drug information for lisdexamfetamine dimesylate [^115K8BAg]. U.S. Food and Drug Administration. High credibility.

Unknown frequency adverse reactions associated with the use of lisdexamfetamine dimesylate PO (also known as Vyvanse) include angioedema, chest pain, dysgeusia, dyskinesia, growth delay, hair loss, headache, mydriasis, Raynaud's phenomenon, rhabdomyolysis, stimulant use disorder, and urticaria.

---

### SPL drug information for lisdexamfetamine dimesylate [^111rTbqP]. U.S. Food and Drug Administration. High credibility.

Common adverse reactions (1–10%) associated with the use of lisdexamfetamine dimesylate PO (also known as Vyvanse) include:

- **Psychiatric and neurological symptoms**: agitation, anxiety, emotional lability, nervousness, nightmares, restlessness, somnolence, tremor, tics
- **Gastrointestinal issues**: constipation, diarrhea, nausea, vomiting
- **Vision and respiratory effects**: blurred vision, dyspnea
- **Cardiovascular effects**: hypertension, palpitations, tachycardia
- **Dermatological reactions**: hyperhidrosis, pruritus, skin rash
- **Other**: decreased libido, dizziness, erectile dysfunction, fever, paresthesia, throat pain, urinary tract infections, weight loss

---

### Drugs in lactation [^114UM8xV]. Seminars in Perinatology (2025). Low credibility.

Medication management in lactation is a challenging topic for healthcare practitioners around the world. In contrast to traditional advice, very few medications are now thought to be absolutely contraindicated in breastfeeding. As data from case reports, quantitative studies of medication transfer to milk, and lactation physiology accumulate, fact-based guidance for use of medications can be increasingly provided.

This review presents the strengths and weaknesses of scientific knowledge underlying recommendations for use of medications during breastfeeding, describes key pharmacokinetic factors influencing infant drug exposure in breastmilk, and provides a practical algorithm and case study on use of clinical resources as well as pharmacologic data to help in the development of a management plan for lactating individuals with various medication needs.

---

### Time course of the effects of lisdexamfetamine dimesylate in two phase 3, randomized, double-blind, placebo-controlled trials in adults with binge-eating disorder [^116pLd9a]. The International Journal of Eating Disorders (2017). High credibility.

The study design and treatment have been previously detailed. In summary, two randomized, placebo-controlled, parallel-group, multicenter studies were conducted, identified by ClinicalTrials.gov as NCT01718483 (Study 1) and NCT01718509 (Study 2). Study protocols were approved by ethics committees and adhered to the International Conference on Harmonisation Good Clinical Practice and the Declaration of Helsinki. Participants provided written informed consent.

Each study featured a 2-week screening phase, a 12-week double-blind phase (consisting of 4 weeks of dose optimization followed by 8 weeks of dose maintenance), and a follow-up visit. Post-screening, participants were randomized in a 1:1 ratio to receive either dose-optimized lisdexamfetamine dimesylate (LDX) or placebo for 12 weeks. Treatments were identical in appearance to maintain blinding. The treatment commenced with 30 mg of LDX in Week 1, increasing to 50 mg in Week 2. By Week 3, doses could be increased to 70 mg based on patient tolerability and clinical need. If the 70 mg dose was poorly tolerated, a down-titration to 50 mg was possible in Week 3, after which no further dose changes were allowed. From Weeks 4 to 12, the optimized dosage (50 or 70 mg) was maintained without further alteration.

---

### Belsomra [^112QEcA1]. U.S. Food and Drug Administration (2025). High credibility.

- **Lactation risk summary**: Suvorexant and its metabolite, hydroxy suvorexant, are present in low concentrations in breast milk with a relative infant dose of less than 1% following maternal oral administration (see Data). There are no data on the effects of suvorexant on the breastfed infant or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Belsomra and any potential adverse effects on the breastfed infant from Belsomra or from the underlying maternal condition.

- **Data**: A single dose (20 mg) milk and plasma lactation study was conducted in 12 healthy lactating women. The mean amount of suvorexant recovered in breast milk was 0.011 mg following a 20 mg maternal dose. The calculated mean daily infant dose was 0.002 mg/kg/day based on the actual infant body weight (i.e. 6.2 kg). The relative infant dose is less than 1% of the maternal dose. Approximately 82% of the amount of suvorexant excreted in breast milk was excreted by 24 hours following a single maternal dose administration. Suvorexant and its metabolite, hydroxy suvorexant, are present in breast milk, and the transfer of hydroxy suvorexant into breast milk is lower than suvorexant (metabolite/parent: 0.13).

- **Pediatric use**: Safety and effectiveness in pediatric patients have not been established.

- **Geriatric use**: Of the total number of patients treated with Belsomra (n = 1784) in controlled clinical safety and efficacy studies, 829 patients were 65 years and over, and 159 patients were 75 years and over.

---

### An infant with a prolonged sympathomimetic toxidrome after lisdexamfetamine dimesylate ingestion [^111xXzme]. Journal of Medical Toxicology (2016). Low credibility.

Stimulant medications are approved to treat attention deficit hyperactivity disorder (ADHD) in children over the age of 6 years. Fatal ingestion of stimulants by children has been reported, although most ingestions do not result in severe toxicity. Lisdexamfetamine dimesylate, a once-daily long-acting stimulant, is a prodrug requiring conversion to its active form, dextroamphetamine, in the bloodstream. Based on its unique pharmacokinetics, peak levels of d-amphetamine are delayed. We describe a case of accidental ingestion of lisdexamfetamine dimesylate in an infant.

- **Case report**: A previously healthy 10-month-old infant was admitted to the hospital with a 5-hour history of tachycardia, hypertension, dyskinesia, and altered mental status of unknown etiology. Confirmatory urine testing, from a specimen collected approximately 16 hours after the onset of symptoms, revealed a urine amphetamine concentration of 22,312 ng/mL (positive cutoff 200 ng/mL). The serum amphetamine concentration, from a specimen collected approximately 37 hours after the onset of symptoms, was 68 ng/mL (positive cutoff 20 ng/mL). Urine and serum were both negative for methamphetamine, methylenedioxyamphetamine (MDA), methylenedioxymethamphetamine (MDMA, Ecstasy), and methylenedioxyethamphetamine (MDEA). During the hospitalization, it was discovered that the infant had access to lisdexamfetamine dimesylate prior to the onset of symptoms.

- **Conclusion**: Amphetamine ingestions in young children are uncommon but do occur. Clinicians should be aware of signs and symptoms of amphetamine toxicity.

---

### Vyvanse [^114Wi9kg]. U.S. Food and Drug Administration (2023). High credibility.

Studies conducted in juvenile rats and dogs at clinically relevant doses showed growth suppression that partially or fully reversed in dogs and female rats but not in male rats following a four-week drug-free recovery period.

In a study, juvenile rats received oral doses of 4, 10, or 40 mg/kg/day of lisdexamfetamine dimesylate from day 7 to day 63 of age. These doses are approximately 0.3, 0.7, and 3 times the maximum recommended human daily dose of 70 mg on a mg/m² basis for a child. Dose-related decreases in food consumption, bodyweight gain, and crown-rump length were observed. After a four-week drug-free recovery period, bodyweights and crown-rump lengths had significantly recovered in females but were still substantially reduced in males. Time to vaginal opening was delayed in females at the highest dose, but there were no drug effects on fertility when the animals were mated beginning on day 85 of age.

In another study, juvenile dogs received lisdexamfetamine dimesylate for 6 months beginning at 10 weeks of age. Decreased bodyweight gain was observed at all doses tested (2, 5, and 12 mg/kg/day, which are approximately 0.5, 1, and 3 times the maximum recommended human daily dose on a mg/m² basis for a child). This effect partially or fully reversed during a four-week drug-free recovery period.

- **Geriatric use**: Clinical studies of Vyvanse did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience and pharmacokinetic data suggest no specific differences related to age.

---

### Study protocol: A double blind placebo controlled trial examining the effect of domperidone on the composition of breast milk [^111dSzL8]. BMC Pregnancy and Childbirth (2006). Low credibility.

What are the proposed outcome measures?

- **Primary outcome**: The protein levels in breast milk, collected on days 0, 4, 7, and 14, will be compared between the two groups, taking into consideration the expected rate of decline associated with increasing postpartum days.

- **Secondary outcomes**: The fat, carbohydrate, lactose, energy, calcium, phosphorus, and sodium content of breast milk, collected on days 0, 4, 7, and 14, will be compared between the domperidone and placebo groups.

- **Other outcomes**: Daily breast milk volumes (estimated, if the infant breastfeeds, using pre and post feeding weights), serum prolactin levels, daily infant weights, and breastfeeding rates two weeks after treatment completion and at discharge.

---

### SPL drug information for lisdexamfetamine dimesylate [^115KDGNh]. U.S. Food and Drug Administration. High credibility.

A boxed warning highlights the risks associated with the use of lisdexamfetamine dimesylate PO, commonly known as Vyvanse, particularly regarding drug abuse, misuse, and stimulant use disorder. It is crucial to exercise extreme caution in all patients.

- **Risk assessment**: Before prescribing lisdexamfetamine, assess the potential for abuse, misuse, and addiction.
- **Continuous monitoring**: Reevaluate the risk throughout the treatment and frequently monitor patients for any signs and symptoms of abuse, misuse, or addiction.

---

### SPL drug information for lisdexamfetamine dimesylate [^114X7x7h]. U.S. Food and Drug Administration. High credibility.

Regarding the use of lisdexamfetamine dimesylate PO (also known as Vyvanse) in patients with any modality, dose as in eGFR < 15 mL/min/1.73 m².

---

### Xenobiotics and breastfeeding [^111nhaVv]. Pediatric Clinics of North America (2001). Low credibility.

Breastfeeding provides important benefits to mothers and infants and should be strongly encouraged as the optimal feeding choice for most infants. In assessing the effects of maternal medication on breastfeeding, clinicians must weigh the many benefits of breastfeeding for mothers and infants against the risk of exposing infants to a drug present in breast milk. With regard to most medications, continuing breastfeeding despite drug exposure is advantageous for both mothers and infants.

---

### The American psychiatric association practice guideline for the treatment of patients with eating disorders [^115FCUKE]. The American Journal of Psychiatry (2023). High credibility.

The drug Lisdexamfetamine dimesylate, also known as Vyvanse, is highlighted.

---

### Study protocol: A double blind placebo controlled trial examining the effect of domperidone on the composition of breast milk [^116r5jta]. BMC Pregnancy and Childbirth (2006). Low credibility.

All authors contributed to the development of the protocol and read and approved the final manuscript.

---

### Halcion [^117Wq4XZ]. U.S. Food and Drug Administration (2025). High credibility.

- **Lactation**: There are reports of sedation, poor feeding, and poor weight gain in infants exposed to benzodiazepines through breast milk. There are no data on the presence of triazolam in human milk or its effects on milk production. Triazolam and its metabolites are present in the milk of lactating rats. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Halcion and any potential adverse effects on the breastfed infant from Halcion or from the underlying maternal condition.

- **Clinical considerations**: Infants exposed to Halcion through breast milk should be monitored for sedation, poor feeding, and poor weight gain. A lactating woman may consider interrupting breastfeeding and pumping and discarding breast milk during treatment and for 28 hours (approximately five elimination half-lives) after Halcion administration to minimize drug exposure to a breastfed infant.

- **Data**: Both triazolam and triazolam metabolites were detected in the milk of rats. Lactating rats were orally administered 0.3 mg/kg 14C-triazolam; drug and metabolite levels were determined in milk collected at 6 and 24 hours after administration.

- **Pediatric use**: Safety and effectiveness of Halcion have not been established in pediatric patients.

- **Geriatric use**: Elderly patients exhibit higher plasma triazolam concentrations due to reduced clearance compared with younger subjects at the same dose.

---

### Paroxetine levels in postpartum depressed women, breast milk, and infant serum [^114X6Eu8]. The Journal of Clinical Psychiatry (2000). Low credibility.

The purpose of this study was to determine the concentrations of paroxetine in maternal serum, breast milk, and infant serum samples and to estimate infant exposure through breastfeeding.

- **Method**: A total of 25 sample sets was obtained: 1 sample set each from 23 mother-infant dyads and 2 sample sets from 1 mother-infant dyad. All mothers met DSM-IV criteria for major depressive disorder. The maternal fixed dosage of paroxetine was 10, 20, or 40 mg/day for a minimum of 30 days before the samples were drawn. Samples were collected 6 hours after dose intake, and the concentration of paroxetine in each sample was determined using gas chromatography/mass spectrometry. The analytic method employed in this study is the most sensitive at the time of writing, with the ability to detect drug concentrations as low as 0.1 ng/mL.

- **Results**: Detectable levels of paroxetine were present in all maternal serum samples and in 24 of the 25 breast milk samples. In all of the infant serum samples, the paroxetine concentrations were below the lower limit of quantification. No unusual adverse effects were reported in any of the infants.

- **Conclusion**: The results of this study demonstrate that paroxetine, like the other selective serotonin reuptake inhibitors studied at the time of writing, is excreted into the breast milk of nursing mothers. The mean infant dose of paroxetine was 1.1% of the maternal dose. Although no short-term adverse effects were reported in any of the infants in this study, future studies are needed to address a more systematic method for observing and recording any adverse effects.

---

### Study protocol: a double blind placebo controlled trial examining the effect of domperidone on the composition of breast milk [^1172Awex]. BMC Pregnancy and Childbirth (2006). Low credibility.

Thus, domperidone, a peripheral dopamine antagonist, may be safer than metoclopramide. Drug levels of domperidone in breast milk are also significantly lower than metoclopramide (p < 0.05). Studies have shown that breast milk samples taken from women receiving either a 10 mg dose of domperidone or a 10 mg dose of metoclopramide contained 10.3 ng/ml of domperidone and 68.5 ng/ml of metoclopramide (p < 0.05). Domperidone has been shown to significantly increase milk production without evidence of adverse effects in the infant. Domperidone has been shown to raise the serum prolactin level in non-lactating women from 8.1 to 110.9 ng/ml after one 20 mg dose.

- **Study design**: In a double-blind placebo-controlled trial, 32 mothers of full-term infants experiencing failure of lactogenesis were randomized to receive either domperidone (10 mg TID) or placebo. Prolactin levels were reported as significantly higher after the 2nd day of treatment in the domperidone group (p < 0.01). The mean daily milk yield was also increased significantly in the domperidone group (p < 0.01), with a corresponding higher infant weight gain.

- **Additional trial results**: In a small double-blind, randomized controlled trial (n = 16), a 7-day course of domperidone (10 mg TID) given to mothers of preterm infants experiencing insufficient milk production resulted in a significantly increased milk supply (p < 0.05), low levels of drug detected in breast milk (< 0.2 mcg/kg/d) and significantly higher maternal prolactin level when compared to the placebo group. No infant or maternal side effects were reported in the above trials.

---

### Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: Infant exposure, clinical symptoms, and cytochrome p450 genotypes [^116oRtY3]. The Journal of Clinical Psychiatry (2004). Low credibility.

The aims of the study were to quantify the drug exposure in breastfed infants of antidepressant-treated mothers, to identify possible adverse events, and to correlate these variables with maternal and infant drug metabolism-relevant genotypes and milk triglyceride content.

- **Method**: The study included 25 lactating women treated with citalopram (N = 9), sertraline (N = 6), paroxetine (N = 6), fluoxetine (N = 1), or venlafaxine (N = 3) and their 26 breastfed infants. Drug concentrations in maternal and infant serum and milk were analyzed using liquid chromatography mass spectrometry methods; milk triglyceride levels were measured with a commercial kit. Cytochrome P450 (CYP) 2D6 and CYP2C19 activity were determined by polymerase chain reaction-based genotyping of the mothers and infants. An infant adverse event questionnaire was completed by the medication-treated mothers as well as by a control group of medication-free breastfeeding mothers of 68 infants.

- **Results**: Sertraline and paroxetine were not detected in any of the drug-exposed infants. The infant serum level of citalopram was either undetectable (N = 4) or low (N = 6). All venlafaxine-exposed infants had measurable drug concentrations. We identified a paroxetine-treated mother and her infant who were both CYP2D6 poor metabolizers, as well as a citalopram-treated mother with CYP2C19 poor metabolizer status, but the serum drug levels of their infants were still either undetectable (paroxetine) or low (citalopram). There was no evidence of adverse events in the drug-exposed infants.

- **Conclusion**: Serum drug levels

---

### Study protocol: A double-blind placebo-controlled trial examining the effect of domperidone on the composition of breast milk [NCT00308334] [^114coMGc]. BMC Pregnancy and Childbirth (2006). Low credibility.

What is the proposed duration of treatment?

The treatment period begins following randomization. It consists of day 0, on which baseline measurements will be taken and recorded. Following this, there is a 14-day treatment period during which domperidone (10 mg × 3/daily) or placebo (3/daily) is administered.

---

### Drugs that affect the fetus and newborn infant via the placenta or breast milk [^117RQePF]. Pediatric Clinics of North America (2004). Low credibility.

In general, drugs taken by a mother during pregnancy or after birth may be transferred to the fetus or the infant through the placenta or breast milk. Many factors determine the amount of drug transferred and their potential effects on the fetus or infant. A careful assessment of the risk versus benefit is necessary and should be individualized. In the breastfed infant, several measures can be undertaken to minimize the amount of drug transferred to the infant.

---

### SPL drug information for lisdexamfetamine dimesylate [^115KiVph]. U.S. Food and Drug Administration. High credibility.

The dosage of lisdexamfetamine dimesylate for the treatment of moderate-to-severe binge eating disorder in adults is as follows: Start with 30 mg orally in the morning. The maintenance dose ranges between 50 mg to 70 mg taken orally in the morning, with a maximum dosage of 70 mg per day.

---

### Study protocol: A double blind placebo controlled trial examining the effect of domperidone on the composition of breast milk [^116nJQzF]. BMC Pregnancy and Childbirth (2006). Low credibility.

Breast milk samples will be obtained on days 0, 4, 7, and 14, while serum prolactin levels will be collected on days 0, 4, and 14. Infant weights will be measured daily. Each participant will be asked questions regarding breast-feeding two weeks following the discontinuation of the treatment and at discharge.

---

### Quzyttir [^112bX99d]. U.S. Food and Drug Administration (2022). High credibility.

- **Lactation**:

	- **Risk summary**: Cetirizine hydrochloride has been reported to be present in human breast milk. In mice and beagle dogs, studies indicated that cetirizine hydrochloride was excreted in milk (see data). When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Quzyttir and any potential adverse effects on the breastfed child from Quzyttir or from the underlying maternal condition.

	- **Data**: Cetirizine hydrochloride was detected in the milk of mice. No adverse developmental effects on pups were seen when cetirizine hydrochloride was administered orally to dams during lactation at a dose that was approximately 10 times the MRHD in adults (see use in specific populations, 8.1). Studies in beagle dogs indicated that approximately 3% of the dose of cetirizine hydrochloride was excreted in milk. The concentration of drug in animal milk does not necessarily predict the concentration of drug in human milk.

---

### Trezix [^111pfDbr]. U.S. Food and Drug Administration (2021). High credibility.

Dihydrocodeine bitartrate and its active metabolite, morphine, are present in human milk. Published studies and cases have reported excessive sedation, respiratory depression, and death in infants exposed to codeine via breast milk. Women who are ultra-rapid metabolizers of dihydrocodeine achieve higher than expected serum levels of morphine, potentially leading to higher levels of morphine in breast milk, which can be dangerous to breastfed infants. In women with normal dihydrocodeine metabolism (normal CYP2D6 activity), the amount of dihydrocodeine secreted into human milk is low and dose-dependent. There is no information on the effects of dihydrocodeine on milk production. Due to the potential for serious adverse reactions, including excess sedation, respiratory depression, and death in a breastfed infant, advise patients that breastfeeding is not recommended during treatment with TREZIX™.

- **Clinical considerations**: If infants are exposed to TREZIX​TM​ through breast milk, they should be monitored for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped or when breastfeeding is stopped.

Acetaminophen and caffeine are also excreted in breast milk in small amounts. Given the potential for serious adverse reactions in nursing infants from this combination product, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

---

### Study protocol: A double blind placebo controlled trial examining the effect of domperidone on the composition of breast milk [NCT00308334] [^113uoabC]. BMC Pregnancy and Childbirth (2006). Low credibility.

**Trial management**: The study nurse will assume the role of study coordinator and will be responsible for the day-to-day management of the trial. The principal investigator will have an active role in the trial, meeting weekly with the study nurse.

---

### Maternal sertraline treatment and serotonin transport in breast-feeding mother-infant pairs [^1149k5u8]. The American Journal of Psychiatry (2001). Low credibility.

The pharmacological treatment of postpartum depression is frequently complicated by the mother's desire to breast-feed. Although breast milk levels of several selective serotonin reuptake inhibitors (SSRIs) have been reported to be relatively low, a critical question is whether SSRI exposure during nursing results in clinically significant blockade of serotonin (5-HT) reuptake in infants. This study determined the degree of transporter blockade in infants exposed to sertraline through maternal breast milk.

The extent of maternal and infant transporter blockade was assessed by measurement of platelet levels of 5-HT in 14 breast-feeding mother-infant pairs before and after 6–16 weeks of maternal treatment with sertraline for major depression with postpartum onset. Plasma sertraline and desmethylsertraline levels were obtained in 13 of these mothers and 11 of their infants.

Marked declines in platelet 5-HT levels of 70%-96% were observed in mothers after sertraline treatment at 25–200 mg/day. In contrast, infants showed little or no change in platelet 5-HT levels after exposure through breast-feeding. Mean levels of maternal plasma sertraline and its major metabolite, desmethylsertraline, were 30.7 ng/ml and 45.3 ng/ml, respectively. Drug and drug metabolite concentrations in the infants were at or below the lower limit of quantitation.

The data indicate that while mothers receiving clinical doses of sertraline experience substantial blockade of the platelet 5-HT transporter, platelet 5-HT uptake in nursing infants of treated mothers is unaffected.

---

### Postpartum varicella vaccination: Is the vaccine virus excreted in breast milk [^116cCPFz]. Obstetrics and Gynecology (2003). Low credibility.

The objective of this study was to evaluate whether the varicella vaccine virus is detected in breast milk after vaccination of breast-feeding women and whether there is serologic evidence of exposure of the infant to the varicella virus after maternal vaccination.

- **Methods**: We enrolled women identified as varicella seronegative during routine prenatal screening at Group Health Cooperative. Participants received the first dose of the varicella vaccine at least 6 weeks postpartum, followed by the second dose at least 4 weeks later. They collected ten breast milk samples after each vaccine dose. These breast milk samples were tested for varicella zoster virus by polymerase chain reaction (PCR). Serum specimens were collected from the mothers 1 month after each vaccine dose. Additionally, peripheral blood from their infants was collected onto filter spots 1 month after the mother's second dose. These samples were tested for varicella immunoglobulin (Ig) G by whole-virus enzyme-linked immunosorbent assay (ELISA) or by the more sensitive glycoprotein ELISA. When possible, filter spots from the infants were also tested by PCR for the presence of varicella zoster virus deoxyribonucleic acid (DNA).

- **Results**: Twelve women were enrolled; all seroconverted after the first vaccine dose. Varicella DNA was not detected by PCR in any of the 217 postvaccination breast milk specimens. None of the infants was seropositive. Samples from six infants were tested for varicella zoster virus DNA by PCR, and all were negative.

- **Conclusion**: We found no evidence of varicella vaccine virus excretion in breast milk. These findings suggest that postpartum vaccination does not pose a risk for excretion of the vaccine virus in breast milk.

---

### Ammonia n 13 [^116tdUKQ]. U.S. Food and Drug Administration (2021). High credibility.

Use in specific populations is as follows. It is not known whether this drug is excreted in human milk. Alternatives to breastfeeding, such as using stored breast milk or infant formula, should be used for 2 hours (> 10 half-lives of radioactive decay for N 13 isotope) after administration of Ammonia N 13 Injection. The safety and effectiveness of Ammonia N 13 Injection have been established in pediatric patients.

- **Pregnancy**: Ammonia N 13 Injection falls under Pregnancy Category C. Animal reproduction studies have not been conducted with this injection. It is not known whether Ammonia N 13 Injection can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. It should be given to a pregnant woman only if clearly needed.

- **Nursing mothers**: As it is not known whether this drug is excreted in human milk and considering that many drugs are excreted in human milk, there is a potential radiation exposure risk to nursing infants from Ammonia N 13 Injection. Therefore, alternative infant nutrition sources, like stored breast milk or infant formula, should be used for 2 hours (> 10 half-lives of radioactive decay for N 13 isotope) after administration of the drug. Alternatively, avoid using the drug, taking into account its importance to the mother.

- **Pediatric use**: The safety and effectiveness of Ammonia N 13 Injection have been established in pediatric patients. This conclusion is based on the known metabolism of ammonia, radiation dosimetry in the pediatric population, and clinical studies in adults. See Dosage and Administration for further information.

---

### British Society of Gastroenterology guidelines on sedation in gastrointestinal endoscopy [^1161188S]. Gut (2024). Low credibility.

In general, most sedative and anesthetic agents have poor oral bioavailability, and although some are excreted into breast milk, the concentrations are low. Midazolam is excreted into breast milk, but the levels are virtually undetectable around 7 hours after administration, with studies finding a level of 0.004% of the maternal dose within 24 hours. The latest national guidance suggests that breastfeeding can recommence once the patient has recovered enough cognitive function. Fentanyl is excreted into breast milk, but the levels are 0.024% within 24 hours of administration, meaning that breastfeeding does not need to be suspended. Pethidine is metabolized to normeperidine, which can cause neurotoxic effects. Normeperidine is concentrated in breast milk and has been associated with neurological effects in breastfeeding children, but one study showed that this was seen only in infants under 6 weeks old. However, there is no evidence that a single intravenous dose of pethidine leads to significant toxicity in breastfeeding infants. Propofol is excreted into breast milk but at very low levels, and the oral bioavailability is low. Breastfeeding after propofol does not need to be suspended and can be resumed as soon as the patient has recovered from anesthesia.

- **Adjunctive medications**: Several other medications are regularly used in patients undergoing gastrointestinal endoscopy, including local anesthetic agents, nitrous oxide, and hyoscine. Local anesthetic agents have been shown to cause fetal bradycardia when used intravenously, but the amounts used in topical applications are significantly lower and generally considered safe for use during procedures.

---

### Unexpected drug residuals in human milk in Ankara, capital of Turkey [^113o6Jfi]. BMC Pregnancy and Childbirth (2019). Low credibility.

The majority of the mothers included in the study had drug residues in their breast milk. These results show that mothers are exposed to drugs in an unexpected manner through foods and, what's more, some of these drugs detected in breast milk are prohibited in humans. In our study, the impact of residues in the mother's milk on baby sleep and crying problems, breastfeeding problems, and postpartum depression (PPD) were not found to be significant. However, drug residues were found to influence the regulation of the anthropometric parameters of the mother.

Preventing unnecessary drug exposure in mother-baby pairs is extremely important for healthy generations. Therefore, veterinary medicinal products must be used in appropriate indications; obedience to appropriate waiting times must be monitored.

---

### SPL drug information for lisdexamfetamine dimesylate [^116WFQKA]. U.S. Food and Drug Administration (Year). High credibility.

Very common adverse reactions (over 10%) associated with the use of lisdexamfetamine dimesylate PO (also known as Vyvanse) include dry mouth, dystonia, epigastric pain, insomnia, irritability, and loss of appetite.

---

### Roxybond [^114pgJYF]. U.S. Food and Drug Administration (2024). High credibility.

Available data from lactation studies indicate that oxycodone is present in breastmilk and that doses of less than 60 mg/day of the immediate-release formulation are unlikely to result in clinically relevant exposures in breastfed infants. A pharmacokinetics study utilizing opportunistic sampling of 76 lactating women receiving oxycodone immediate-release products for postpartum pain management showed that oxycodone concentrates in breastmilk with an average milk to plasma ratio of 3.2. The relative infant dose was low, approximately 1.3% of a weight-adjusted maternal dose (see Data).

In the same study, among the 70 infants exposed to oxycodone in breastmilk, no adverse events were attributed to oxycodone. However, based on known adverse effects in adults, infants should be monitored for signs of excess sedation and respiratory depression. There are no data on the effects of oxycodone on milk production.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Roxybond and any potential adverse effects on the breastfed infant from Roxybond or from the underlying maternal condition.

- **Clinical considerations**: Monitor infants exposed to Roxybond through breast milk for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped or when breastfeeding is stopped.

---

### 68ga-dotatate breast uptake and expression in breast milk [^113g4eBy]. Clinical Nuclear Medicine (2016). Low credibility.

The excretion of Ga-DOTA-Octreotate (DOTATATE) and related somatostatin analogues in breast milk has not been demonstrated. We report a case of a 34-year-old woman, 7 months postpartum and breastfeeding, who was referred for DOTATATE imaging after the diagnosis of appendiceal carcinoid and subsequent appendectomy. Prominent breast uptake was noted. A breast milk sample from the patient at 90 minutes post-injection was assayed in a gamma counter and shown to have a concentration of 5.6 Bq/g per MBq administered. The excretion of DOTATATE in breast milk is important to consider when providing radiation safety advice to breastfeeding patients.

---

### Adderallxr [^113pXK2f]. U.S. Food and Drug Administration (2025). High credibility.

AdderallXR is present in human milk at relative infant doses of 2 to 13.8% of the maternal weight-adjusted dosage, with a milk/plasma ratio ranging between 1.9 and 7.5. There are no reported adverse effects on the breastfed infant. However, the long-term neurodevelopmental effects on infants from amphetamine exposure remain unknown. Large dosages of amphetamine may interfere with milk production, particularly in women whose lactation is not well established. Due to the potential for serious adverse reactions in nursing infants, it is advised that patients do not breastfeed while undergoing treatment with AdderallXR.